



## Effects of kefir on liver function tests and histopathological changes in rats exposed to aflatoxin B<sub>1</sub>

Seyed Ahmad Sajjadi<sup>1</sup>, Abdollah Jamshidi<sup>2\*</sup>, Farhad Niknejad<sup>3</sup>, Zahra Moosavi<sup>1</sup>

<sup>1</sup>. Department of Food Hygiene and Aquaculture, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran

<sup>2</sup>. Department of Medical Mycology, Department of Laborator Sciences, Golestan University of Medical Sciences, Gorgan, Iran

<sup>3</sup>. Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran

\*Correspondence: Abdollah Jamshidi. Department of Food Hygiene and Aquaculture, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran. Tel: +989105183386; Email: [ajamshid@ferdowsi.um.ac.ir](mailto:ajamshid@ferdowsi.um.ac.ir)

### Article History

Received: 8 August 2022

Received in revised form: 6 September 2022

Accepted: 8 September 2022

Published online: 2 September 2022

DOI: 10.29252/MLJ.17.3.17

### Keywords

Kefir  
Aflatoxin B<sub>1</sub>  
Probiotics  
Liver functions  
Histopathological changes

Article Type: Original Article



### Abstract

**Background:** Aflatoxin B<sub>1</sub> (AFB<sub>1</sub>) is one of the most important mycotoxins that contaminate food worldwide. Long-term consumption of foods contaminated with AFB<sub>1</sub> endangers human health. Detoxification of AFB<sub>1</sub> from food improves community health. A Specific approach to aflatoxin reduction is the use of probiotics. Kefir drink is a strong probiotic. The purpose of this study was to investigate the protective effect of kefir drink on AFB<sub>1</sub>-induced hepatic injury in adult male rats

**Methods:** In this experimental study, 48 adult rats weighing between 100 and 120 g were used. The rats were randomly divided into 4 groups: 1) control, 2) AFB<sub>1</sub> (20 µg/kg body weight), 3) kefir drink (1 mL/kg body weight), and 4) AFB<sub>1</sub> + kefir drink. Aflatoxin and kefir drink received through oral gavage. At the end of the experiment (4 weeks), blood and liver samples were collected for different assays. Liver function tests and histopathological examinations were performed. Data were analyzed using 1-way analysis of variance (ANOVA) and at a significance level of <math>P < 0.05</math>.

**Results:** Aflatoxin B<sub>1</sub> significantly increased serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (T.Bili), as well as decreased total protein (T.P) content, compared to the control group ( $P < 0.05$ ). Aflatoxin B<sub>1</sub> induced histological changes in the liver. The results obtained from the groups treated with kefir drink with and without AFB<sub>1</sub> were not significantly different from the control group. Histopathological changes were not found in groups treated with kefir drink with and without AFB<sub>1</sub>.

**Conclusion:** The consumption of kefir drink reduced AFB<sub>1</sub>-induced disruptions in rats' livers.

### Introduction

Aflatoxins are one of the most important types of mycotoxins produced as secondary fungal metabolites by *Aspergillus* genera (mainly *Aspergillus flavus* and *A. parasiticus*) that contaminate food and animal feed worldwide (1). More than 14 types of aflatoxin have been introduced. Among them are aflatoxin B<sub>1</sub> (AFB<sub>1</sub>), AFB<sub>2</sub>, AFG<sub>1</sub>, and AFG<sub>2</sub>, which significantly contaminate food sources. In addition, AFM<sub>1</sub> and AFM<sub>2</sub> are synthesized in the animal body that consumes food contaminated with AFB<sub>1</sub> and AFB<sub>2</sub> (2). A published epidemiological study showed a strong association between AFB<sub>1</sub> use and cancer incidence, and the International Agency for Research on Cancer (IARC) has classified AFB<sub>1</sub> as a group 1 carcinogen (3). The main biological effects of aflatoxins are acute and chronic liver disease, but liver toxicity, carcinogenicity, mutagenicity, teratogenicity, and suppression of the immune system are also among their effects (4). Long-term consumption of foods contaminated with aflatoxins can damage liver cells, impair their function, and cause significant changes in biochemical parameters associated with liver activity.

Numerous physical, chemical, and biological methods have been used to detoxify and eliminate aflatoxins in animal feed and food. In most of these methods, by modifying or destroying the molecular structure or absorbing toxins, they eliminate or reduce the transfer of toxins in the gastrointestinal tract, inhibiting and reducing their access to target tissues. However, the use of these methods is limited due to nutrient degradation, loss of organoleptic properties, the presence of new residues, and the need for expensive equipment (5). An easy, cheap, and healthy way to eliminate or reduce aflatoxins is to use healthy foods. Healthy foods are products that, in addition to providing basic nutrition, increase people's health. Among healthy foods, foods containing probiotic microorganisms are of special importance. According to the World Health Organization (WHO) and the Food and Agriculture Organization of the United Nations (FAO), probiotics are living microorganisms that, when consumed in sufficient quantities, promote health in the host (6). Kefir drink is a strong probiotic fermented dairy product that is produced by incubating kefir grains in milk. Kefir grains contain yeasts and bacteria of lactic acid and acetic acid, which are integrated into a polysaccharide background and form small masses similar to cauliflower. During fermentation, existing bacteria and yeasts grow and multiply to produce lactic acid, acetic acid, ethanol, aromatic

compounds, essential amino acids, vitamins, minerals, and exopolysaccharides (7).

Antimicrobial, anti-cancer, anti-inflammatory, and immunosuppressive effects have been reported for kefir grains and their products. It is also used in the treatment of gastrointestinal disorders, hypertension, allergies, and cardiovascular diseases (8). Recently, probiotics have shown beneficial results in detoxifying and reducing the destructive effects of toxins, including aflatoxins, in and out of the body (9).

This study investigated the chronic effects of AFB<sub>1</sub> on hepatic cell synthesis function in adult male Wistar rats, as well as the effect of kefir drink as a potent probiotic in reducing or eliminating these effects.

### Methods

Aflatoxin B<sub>1</sub> from *A. flavus* was purchased from Sigma-Aldrich (CAS number: 1116-76-8, Aryatajiz Company, Tehran, Iran). Human biochemical kits, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein (T.P), and total bilirubin (T.Bili) were purchased from Pars Azmun Company (Tehran, Iran), and kefir grains were obtained from a local traditional market of probiotic dairy products (Gorgan, Iran).

Kefir drink was manufactured by pasteurized fresh cow milk inoculated with 0.7% (w/v) kefir grains and incubated in a glass bottle at 20 °C for 24 hours. At the end of the fermentation process, kefir grains were separated from fermented milk by a sterile plastic sieve and stored for later use. The strained product, which is called kefir drink, was used to feed rats. According to The Codex Alimentarius standards for kefir, the minimum number of bacteria per mL should be 1.0 × 10<sup>7</sup> and 1.0 × 10<sup>8</sup> for yeasts (10).

In the present study, 48 adult male Wistar rats weighing between 100 and 120 g were obtained from the Pasteur Institute of Iran and transferred to the animal house of Gorgan University of Medical Sciences. The rats were housed in a controlled unit under standard temperature and humidity conditions (22 ± 2 °C, 12-hour light/dark cycle). During the experimental period, standard

commercial rat feed (pellet feed) and tap water ad libitum were provided to the rats (basal diet). All of the animal experiments were carried out in accordance with the guideline for the care and use of laboratory animals in Iran (11). After a 1-week adaptation period, the animals were randomly divided into 4 experimental groups (n = 6 for each group) as follows:

- Group N (the control group): The rats were fed on a basal diet.
- Group A: The rats were fed on a basal diet and orally administered with AFB<sub>1</sub> (0.05 μg/kg body weight).
- Group K: The rats were fed on a basal diet and orally administered with kefir drink (1.0 mL/kg body weight).
- Group AK: The rats were fed on a basal diet and orally administered with AFB<sub>1</sub> (0.05 μg/kg body weight), followed by a kefir drink (1.0 mL/kg body weight).

The doses of AFB<sub>1</sub> used in this study were selected according to previous studies (12).

At the end of the experiment (4 weeks), the rats were fasted overnight and anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (10 mg/kg). Then, blood samples (2 mL) from each rat were collected directly from the heart and poured into normal tubes. The sera were carefully transferred to clean tubes, analyzed, and stored at -20 °C until use for the determination of the biochemical parameters. At the beginning and end of the experimental period, the weight of the rats was measured in all groups.

After dissection, liver tissues were collected for histopathological evaluation, fixed in 10% formalin solution, and sent to the pathology laboratory for the preparation of tissue sections using a Shandon Citadel 1000 Tissue Processor (England) and hematoxylin and eosin (H&E) staining.

The measurement of aminotransferase enzyme activity levels was performed according to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and ALP activity was measured by the photometric method according to the German Society for Clinical Chemistry. The concentration of T.P was measured by following the Biuret method. Total bilirubin was measured photometrically using 2, 6-dichloroaniline (DCA) (13).

Data were statistically analyzed using SPSS version 16 (SPSS Inc, Chicago, IL, USA). One-way analysis of variance (ANOVA) was used to examine the significant difference between the different means at P < 0.05.

**Results**

The results after 4 weeks of treatment showed that the weight gain (%) of the rats in group A (30.1%) was lower than the control group (47.1%), while the weight gain of the rats in K (44.9%) and AK (40.9%) groups was not different compared to the control group (Table 1).

**Table 1.** The results of changes in weight gain of the rats in all groups after 4 weeks of treatment with or without aflatoxin B<sub>1</sub> (0.05 μg/kg body weight) percentage weight gain = (final weight - initial weight)/initial weight × 100.

Rat groups	Initial weight (g)	Final weight (g)	Weight gain (g)	Weight gain %
Control (group N)	116.8 ± 2.3	174.8 ± 3.7	58	47.1
AFB <sub>1</sub> (group A)	115.0 ± 2.0	150.5 ± 2.1	35.5	* 30.9
Kefir (group K)	110.0 ± 1.3	160.3 ± 2.2	50.3	44.9
AFB <sub>1</sub> + kefir (group AK)	118.0 ± 1.8	167.7 ± 2.1	49.7	40.9

\* Significant as compared to other groups

In group A, AST, ALT, ALP, and T.Bili increased significantly compared to the control group and groups treated with or without kefir (P < 0.05). T.P levels were significantly reduced (P < 0.05) in group A compared to the other groups (Table 2).

The liver sections of group A showed a disrupted lobular architecture and mild to severe degenerative changes, which were characterized by swelling and


**Table 2.** The results of Liver Function Tests in all groups after 4 weeks of treatment with or without aflatoxin B<sub>1</sub> (0.05 μg/kg body weight)

	Control group	Group A	Group K	Group AK
AST (U/L)	119.6 ± 10.6	179.8 ± 6.3 *	123.2 ± 11.2	118.1 ± 9.7 **
ALT (U/L)	70.3 ± 7.3	90.3 ± 9.7 *	70.0 ± 7.1	70.0 ± 0.2 **
ALP (U/L)	407.6 ± 80.0	508.0 ± 104.9 *	413.0 ± 07.2	489.2 ± 77.2 **
T. Bili (mg/dL)	0.29 ± 0.04	0.72 ± 0.10 *	0.20 ± 0.02	0.26 ± 0.02 **
T. P (g/dL)	7.24 ± 0.33	0.70 ± 0.07 *	7.03 ± 0.21	7.02 ± 1.20 **

Data are expressed as means ± SD for 6 rats per group Significance was calculated at P < 0.05; \* Significant as compared to control animals; \*\* Significant as compared to AFB<sub>1</sub> treated animals Abbreviations: AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; ALP, Alkaline phosphatase; T.Bili, Total bilirubin; T.P, Total protein

vacuolar appearance of hepatocytes (Figure 1B). Kefir administration decreased liver failure caused by AFB<sub>1</sub> intoxication (Figure 1D). The liver of rats fed on a basal diet (Figure 1A) or supplemented with kefir (Figure 1C) showed a normal liver structure characterized by normal hepatocytes arranged as cords.

**Figure 1.** The hepatic sections of the control group (A), AFB<sub>1</sub> group (B), kefir group (C), and AFB<sub>1</sub> + kefir group (D) following hematoxylin and eosin



staining. Histopathological changes in the liver of AFB<sub>1</sub>-treated rats show swelling and vacuolar cytoplasm (arrows).

**Discussion**

Previous studies have confirmed that AFB<sub>1</sub> causes serious damage to the liver, leading to significant changes in liver function tests. Mosaad et al. (14) showed that treatment with AFB<sub>1</sub> resulted in a significant decrease in body weight and T.P and increased ALT, AST, creatinine, uric acid, and urea compared to the control group (14).

Aflatoxin B<sub>1</sub> is mainly biotransformed in the liver (15) through the action of the cytochrome P450 enzyme family (CYP450), resulting in the conversion of AFB<sub>1</sub> into other metabolites. It is important to note that several of these metabolites are highly toxic (such as AFB<sub>1</sub>-8,9-epoxide [AFBO]). AFB<sub>1</sub> has oxidative activity and can cause oxidative damage to hepatocytes directly or via promoting reactive oxygen species (ROS) production. AFB<sub>1</sub> is a highly reactive compound that forms adducts with amino acids and nucleic acids. DNA adducts are relatively resistant to DNA repair processes, causing gene mutations that lead to cancers, especially liver cell carcinomas. Other metabolites can cause acute toxicity, liver necrosis, and inhibition of cellular metabolizing enzymes, resulting in impaired metabolism of substances in the liver (16). Gaspar et al (17) showed that kefir could moderate the activity of antioxidant enzymes and remove free radicals like a scavenger, thus reducing oxidative stress (17). Lactobacilli and bifidobacteria strains found in kefir could reduce oxidative stress by scavenging free radicals and reducing lipid peroxidation (18). Intracellular ALT, AST, and ALP are released into the peripheral blood, increasing the concentration of these enzymes in the serum when hepatocytes undergo damage. In addition, the ability of hepatocyte to ingest, transform, and excrete bilirubin is reduced, resulting in elevating levels of serum bilirubin. Therefore, serum ALT, AST, ALP, and bilirubin can serve as biomarkers of liver dysfunction. In this study, the increase of AST, ALT, ALP, and T. Bili, as well as the decrease of T.P in group A, provided strong evidence of serious injury in the liver. However, the lack of significant differences in AST, ALT, ALP, T. Bili, and T.P in group AK compared to the control group gives a clue that kefir has an obvious positive effect in alleviating AFB<sub>1</sub>-induced liver damage. Sahar Abdel-Mogheith et al (19) reported similar results in an experimental model of carbon tetrachloride-induced liver damage, in which kefir-treated animals maintained normal liver function tests (19).

Aflatoxin is known to impair protein biosynthesis AFB<sub>1</sub> by forming additional compounds with RNA and DNA and proteins by inhibiting RNA synthesis, decreasing the synthesis of DNA-dependent RNA polymerase, and inhibiting the transfer of amino acids and mRNA transcription. It disrupts the synthesis of proteins (20). The reduction of T.Ps in group A compared to the control group showed that the oral administration of AFB<sub>1</sub> caused disruption in liver synthesis, while T.Ps in group AK were not significantly different from the control group. These biochemical findings were similar to those reported by Ozturk and Guven (21) (21). The results obtained from several studies show that kefir grains, kefir drink microorganisms isolated from kefir, and substances extracted from kefir are able to eliminate or reduce the effects of aflatoxin toxicity through different mechanisms (22). In a study for optimizing the amount of AFB<sub>1</sub> reduction in pistachio nuts by kefir grains, it was found that kefir grains could significantly reduce the amount of AFB<sub>1</sub>, and the cell viability of kefir grains was not necessary for its decontamination effect (23). Eiri et al isolated *Saccharomyces cerevisiae* and *Kluyveromyces marcianus* from kefir and showed that they absorbed 46% and 0.3%, respectively, in a broth medium (24, 25). Tahour et al (26) demonstrated that kefir could adsorb 87% to 100% of AFB<sub>1</sub> when cultivated in milk and consequently reduce their toxicity (27, 28). Furthermore, the reduction of oxidative stress biomarkers could be attributed to the non-availability of a part of AFB<sub>1</sub> in rat organisms.

## Conclusion

Our study showed that kefir drink could reduce the damage caused by AFB<sub>1</sub> in adult rats. Previous studies have also confirmed these results. Regular consumption of kefir drink appears to have potential benefits for human health.

## Acknowledgement

The authors would like to thank the staff of Gorgan University of Medical Sciences and all those who helped them in this research.

## Funding sources

This research was financially supported by the Ferdowsi University of Mashhad

## Ethical statement

The study was approved by the Ethics Committee of Ferdowsi University of Mashhad (Code: IR.UM.REC.1398.108).

## Conflicts of interest

The authors declare that there is no conflict of interest regarding the publication of this article.

## Author contributions

A.S performed the experiments. H. J supervised the research. F.N supervised the research and planned the experiments. Z.M contributed to data analysis of histopathology. All authors contributed equally to writing the final paper.

## References

- Gruber-Dorninger C, Jenkins T, Schatzmayr G. Global mycotoxin occurrence in feed: a ten-year survey. *Toxins(Basel)*. 2019;11(7):370. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Kumar P, Mahato DK, Kamle M, Mohanta TK, Kang SG. Aflatoxins: A global concern for food safety, human health and their management. *Front Microbiol*. 2017;8:2117. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Nazhand A, Durazzo A, Lucarini M, Souto EB, Santini A. Characteristics, occurrence, detection and detoxification of aflatoxins in foods and feeds. *Foods*. 2020;9(5):644. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Rushing BR, Selim MI. Aflatoxin B<sub>1</sub>: A review on metabolism, toxicity, occurrence in food, occupational exposure, and detoxification methods. *Food Chem Toxicol*. 2019;124:1-10. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Sipos P, Peles F, Brassó DL, Béri B, Pusztahelyi T, Pócsi I, et al. Physical and chemical methods for reduction in aflatoxin content of feed and food. *Toxins(Basel)*. 2021;13(3):204. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Afshar P, Shokrzadeh M, Raeisi SN, Ghorbani-HasanSaraei A, Nasirai LR. Aflatoxins biotransformation strategies based on probiotic bacteria. *Toxicon*. 2020;198:50-58. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Rosa DD, Dias MM, Grzeźkowiak ŁM, Reis SA, Conceição LL, Maria do Carmo GP. Milk kefir: nutritional, microbiological and health benefits. *Nutr Res Rev*. 2017;30(1):82-96. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Sharifi M, Moridnia A, Mortazavi D, Salehi M, Bagheri M, Sheikhi A. Kefir: a powerful probiotics with anticancer properties. *Med Oncol*. 2017;34(11):183. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Zolfaghari H, Khezerlou A, Ehsani A, Khosroushahi AY. Detoxification of Aflatoxin B<sub>1</sub> by probiotic Yeasts and Bacteria isolated from dairy products of Iran. *Adv Pharm Bull*. 2020;10(3):482-9. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Joint FAO, WHO Food Standards Programme. Codex Alimentarius: Food hygiene basic texts. 7th ed. Rome:Food & Agriculture Org; 2004. p.78 [View at Publisher] [Google Scholar]
- Ahmadi-Noorbakhsh S, Mirabzadeh Ardakani E, Sadighi J, Aldavood SJ, Farajli Abbasi M, Farzad-Mohajeri S, et al. Guideline for the care and use of laboratory animals in Iran. *Lab Anim(NY)*. 2021;50(11):232-9. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Meki A-RM, Abdel-Ghaffar SK, El-Gibaly I. Aflatoxin B<sub>1</sub> induces apoptosis in rat liver: protective effect of melatonin. *Neuro Endocrinol Lett*. 2007;28(6):417-26. [View at Publisher] [Google Scholar] [PMID]
- Thomas L. Clinical laboratory diagnostics. 10th ed. Frankfurt TH:Books Verlagsgesellschaft;1998. [View at Publisher] [Google Scholar]
- Abdel-Wahhab MA, El-Nekeety AA, Hathout AS, Salman AS, Abdel-Aziem SH, Sabry BA, et al. Bioactive compounds from *Aspergillus niger* extract enhance the antioxidant activity and prevent the genotoxicity in aflatoxin B<sub>1</sub>-treated rats. *Toxicon*. 2020;181:57-68. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Bbosa GS, Kitya D, Odda J, Ogwal-Okeng J. Aflatoxins metabolism, effects on epigenetic mechanisms and their role in carcinogenesis. *Health*. 2013;5(10A):14-24. [View at Publisher] [Google Scholar] [DOI]
- Gaspar-Pintiliecu A, Oancea A, Cotarlet M, Vasile AM, Bahrim GE, Shaposhnikov S, et al. Angiotensin-converting enzyme inhibition, antioxidant activity and cytotoxicity of bioactive peptides from fermented bovine colostrum. *International Journal of Dairy Technology*. 2020;23(1):108-16. [View at Publisher] [Google Scholar] [DOI] [PMID]
- Rosa DD, Peluzio MdCG, Bueno TP, Cañizares EV, Miranda LS, Dorbigny BM, et al. Evaluation of the subchronic toxicity of kefir by oral administration in Wistar rats. *Nutr Hosp*. 2014;29(6):1302-9. [View at Publisher] [Google Scholar] [DOI] [PMID]
- AbdEl-Mogheith S, El-Gendy AO, Sultan S, El-Nesr KA. Exploring the antimicrobial and hepatoprotective effects of kefir: a probiotic fermented milk. *J Pure Appl Microbiol*. 2017;11(2):209-22. [View at Publisher] [Google Scholar] [DOI]
- Wade M, Sapkota D, Verma U. Ameliorating aflatoxicosis in commercial broiler chickens by dietary Mycosorb: Heamato-Biochemical studies. *Indian Journal of Animal Research*. 2018;52(1):6-9. [View at Publisher] [Google Scholar] [DOI]
- Ozturk B, Guven A. Effect of kefir on gene expression profiles of GSTM1 and GSTT1 with antioxidant defence in the environment of detoxification of aflatoxin an in vivo study. *International Journal of Basic and Clinical Studies (IJBCS)*. 2014;3(1):9-24. [Google Scholar]
- Taheur FB, Mansour C, Chaieb K. Application of Kefir probiotics strains as aflatoxin B<sub>1</sub> binder in culture medium, milk and simulated gastrointestinal conditions. *Conference on Molecular Biomed Comput & Network Science and Engineering*. 2021. [View at Publisher] [Google Scholar] [DOI]
- Ansari F, Rezaei K, Khodaiyan F, Rahmani A. Optimisation of aflatoxin B<sub>1</sub> reduction in pistachio nuts by kefir grains using statistical experimental methods. *Quality Assurance and Safety of Crops & Foods*. 2020;14(4):509-18. [View at Publisher] [Google Scholar] [DOI]
- Eiri A, Niknejad F, Ardebili A. Detoxification of AFB<sub>1</sub> by Yeasts Isolates from Kefir and Traditional Kefir-Like Products. *Medical Laboratory Journal*. 2022;16(4):200. [View at Publisher] [Google Scholar] [DOI]
- Taheur FB, Fedhila K, Chaieb K, Kouidhi B, Bakhrout A, Abrunhosa L. Adsorption of aflatoxin B<sub>1</sub>, zearalenone and ochratoxin A by microorganisms isolated from Kefir grains. *Int J Food Microbiol*. 2017;251:1-7. [View at Publisher] [Google Scholar] [DOI] [PMID]

## How to Cite:

Sajjadi A, Jamshidi A, Niknejad F, Moosavi Z. Effects of kefir on liver functional tests and histopathological changes in rats exposed to aflatoxin B<sub>1</sub>. *Med Lab J*. Jul-Aug 2023;17(4):17-9.

